Should You Sell Amedisys Today?

Should you sell Amedisys (Nasdaq: AMED) today?

The decision to sell a stock you've researched and followed for months or years is never easy. If you fall in love with your stock holdings, you risk becoming vulnerable to confirmation bias -- listening only to information that supports your theories, and rejecting any contradictions.

In 2004, longtime Fool Bill Mann called confirmation bias one of the most dangerous components of investing. This warning has helped my own personal investing throughout the Great Recession. Now, I want to help you identify potential sell signs on popular stocks within our 4-million-strong Fool.com community.

Today I'm laser-focused on Amedisys, ready to evaluate its price, valuation, margins, and liquidity. Let's get started!

Don't sell on price
Over the past 12 months, Amedisys is down 44.3% versus an S&P 500 return of 11.3%. Investors in Amedisys are no doubt disappointed with their returns, but is now the time to cut and run? Not necessarily. Short-term underperformance alone is not a sell sign. The market may be missing the critical element of your Amedisys investing thesis. For historical context, let's compare Amedisys' recent price to its 52-week and five-year highs. I've also included a few other businesses in the same or related industries:

Source: Capital IQ, a division of Standard & Poor's.

As you can see, Amedisys is well below its 52-week high. If you bought near the peak, now's the time to think back to why you bought it in the first place. If your reasons still hold true, you shouldn't sell based on this information alone.

Potential sell signs
First up, we'll get a rough idea of Amedisys' valuation. I'm comparing Amedisys' recent P/E ratio of 4.8 to where it's been over the past five years.

Source: Capital IQ, a division of Standard & Poor's.

Amedisys' P/E is lower than its five-year average, which could indicate the stock is undervalued. A low P/E isn't always a good sign, since the market may be lowering its valuation of the company because of less attractive growth prospects. It does indicate that, on a purely historical basis, Amedisys looks cheap.

Now, let's look at the gross margins trend, which represents the amount of profit a company makes for each $1 in sales, after deducting all costs directly related to that sale. A deteriorating gross margin over time can indicate that competition has forced the company to lower prices, that it can't control costs, or that its whole industry's facing tough times. Here is Amedisys' gross margin over the past five years:

Source: Capital IQ, a division of Standard & Poor's.

Despite a dip in 2006, Amedisys has maintained its gross margin within a five-percentage-point range. This is solid news; however, Amedisys investors need to keep an eye on this over the coming quarters. If margins continue to dip, you'll want to know why.

Next, let's explore what other investors think about Amedisys. We love the contrarian view here at Fool.com, but we don't mind cheating off of our neighbors every once in a while. For this, we'll examine two metrics: Motley Fool CAPS ratings and short interest. The former tells us how Fool.com's 170,000-strong community of individual analysts rate the stock. The latter shows what proportion of investors are betting that the stock will fall. I'm including other peer companies once again for context.

Source: Capital IQ, a division of Standard & Poor's.

The Fool community is rather bearish on Amedisys. We typically like to see our stocks rated at four or five stars. Anything below that is a less-than-bullish indicator. I highly recommend you visit Amedisys' stock pitch page to see the verbatim reasons behind the ratings.

Here, short interest is at a high 24.1%. This typically indicates that large institutional investors are betting against the stock.

Now, let's study Amedisys' debt situation, with a little help from the debt-to-equity ratio. This metric tells us how much debt the company's taken on, relative to its overall capital structure.

Source: Capital IQ, a division of Standard & Poor's.

Amedisys has been taking on some additional debt over the past five years. When we take into account increasing total equity over the same time period, this has caused debt-to-equity to increase, as seen in the above chart. Based on the trend alone, that's a bad sign. I consider a debt-to-equity ratio below 50% to be healthy, though it varies by industry.  Amedisys is currently below this level, at 24.7%.

The last metric I like to look at is the current ratio, which lets investors judge a company's short-term liquidity. If Amedisys had to convert its current assets to cash in one year, how many times over could the company cover its liabilities? As of the last filing, Amedisys has a current ratio of 1.22. Amedisys could cover its liabilities, but it's still below a healthy level of 1.5.

Finally, it's highly beneficial to determine whether Amedisys belongs in your portfolio -- and to know how many similar businesses already occupy your stable of investments. If you haven't already, be sure to put your tickers into Fool.com's free portfolio tracker, My Watchlist. You can get started right away by clicking here to add Amedisys.

The final recap

Amedisys has failed four of the quick tests that would make it a sell. Does it mean you should sell your Amedisys shares today solely because of this? Not necessarily, but keep your eye on these trends over the coming quarters.

Remember to add Amedisys to My Watchlist  to help you keep track of all our coverage of the company on Fool.com.

If you haven't had a chance yet, but sure to read this article detailing how I missed out on over $100,000 in gains through wrong-headed selling.